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ABSTRACT
Tumorigenesis results from the convergence of cell autonomous mutations and 
corresponding stromal changes that promote tumor cell growth.  Senescent cells, 
which secrete a plethora of pro-tumorigenic factors termed the senescence-associated 
secretory phenotype (SASP), play an important role in tumor formation.  Investigation 
into SASP regulation revealed that many but not all SASP factors are subject to 
NF-kB and p38MAPK regulation.  However, many pro-tumorigenic SASP factors, 
including osteopontin (OPN), are not responsive to these canonical pathways leaving 
the regulation of these factors an open question.  We report that the transcription 
factor c-Myb regulates OPN, IL-6, and IL-8 in addition to 57 other SASP factors.  
The regulation of OPN is direct as c-Myb binds to the OPN promoter in response to 
senescence.  Further, OPN is also regulated by the known SASP regulator C/EBPβ.  
In response to senescence, the full-length activating C/EBPβ isoform LAP2 increases 
binding to the OPN, IL-6, and IL-8 promoters.  The importance of both c-Myb and C/
EBPβ is underscored by our finding that the depletion of either factor reduces the 
ability of senescent fibroblasts to promote the growth of preneoplastic epithelial cells.
INTRODUCTION
Age is a major risk factor in the development of 
cancer [1]. In addition to the accumulation of epithelial 
cell mutations, age-dependent changes in the stromal 
compartment play an important role in tumor promotion 
[2–7]. One of these changes is the accumulation of 
senescent stromal cells that possess the ability to stimulate 
preneoplastic and neoplastic cell growth. First described as 
an in vitro phenomenon caused by repeated cell divisions, 
senescence can also be caused by a number of genotoxic 
stresses including telomere shortening or dysfunction, 
DNA double strand breaks, oxidative stress, tumor 
suppressor expression, and oncogene activation [8–10]. 
Senescent cells are associated with a flattened morphology, 
the presence of heterochromatic foci (SAHFs), positive 
senescence-associated β-galactosidase staining, and 
an altered gene expression and secretion profile termed 
the senescence-associated secretory phenotype [SASP; 
11–14]. Significantly, senescence is now known to occur 
both in vitro and in vivo [9, 11, 15–18] where it impacts 
a diverse number of biologic processes including cancer.
Senescence acts as a potent tumor suppressive 
mechanism in a cell autonomous setting by preventing the 
proliferation of cells with activated oncogenes or excessive 
DNA damage. However, as individuals age, senescent 
cells accumulate within tissues where they are postulated 
to contribute to aging phenotypes [11, 12]. Aged mice 
cleared of p16Ink4a-positive senescent cells have reduced 
incidences of several age-related pathologies, including 
reduced tumor rates [2, 19]. Further, senolytic drugs that 
target senescent cells can ameliorate many age-related 
maladies, underscoring the importance of these cells in 
age related diseases [20–22]. Additionally, the largest risk 
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factor for cancer is age, and there is significant evidence 
that accumulating senescent cells paradoxically contribute 
to cancer development and progression in a cell non-
autonomous fashion. As with other age-related diseases, 
elimination of senescent cells reduces spontaneous tumor 
rates in naturally aged mice [19, 22]. The SASP can 
promote growth and transformation of epithelial cells in 
numerous models, suggesting that secretion of the SASP 
by accumulating senescent cells may contribute to age-
related tumorigenesis [3, 4, 7, 13, 14, 23–25].
The SASP consists of numerous secreted factors 
including cytokines, mitogens, and extracellular matrix 
remodelers that are upregulated at the mRNA and protein 
levels [7, 14]. The regulation of SASP expression is 
complex and incompletely understood, but recent work has 
revealed that both the cell type and senescence inducer can 
significantly impact the mechanisms that regulate SASP 
expression as well as the specific SASP factors expressed 
[26, 27]. The expression of many factors, including 
the canonical SASP factors IL-6 and IL-8, requires 
p38MAPK, ATM, and NF-κB for transcriptional activation 
[5, 8, 14, 28, 29]. Additionally, p38MAPK regulates many 
SASP factors via post-transcriptional stabilization of their 
mRNA (6). However, not all SASP factors are regulated 
by these same pathways. For instance, while p38MAPK is 
an important regulator of the SASP, one study found that it 
regulated only 25 of 37 factors studied at the protein level 
while we previously reported that it regulates only 50 of 
248 factors at the mRNA level in our model [5, 6].
One such factor is osteopontin (OPN), a pro-
tumorigenic protein which has numerous physiological 
and pathological roles, including regulating bone turnover, 
cell adhesion and migration, and inflammation [30–33]. 
OPN is a secreted matrix protein that is upregulated in 
response to wounds, acts to recruit immune cells, can 
suppress apoptosis, and is upregulated and diagnostically 
relevant in a number of cancer types [32, 34–36]. OPN 
is also robustly upregulated in response to senescence. 
Previously we showed that senescent BJ skin fibroblasts 
lose the ability to promote preneoplastic cell growth when 
they are depleted of OPN. Furthermore, recombinant 
OPN induces preneoplastic cell growth in the absence of 
senescent cells [7, 37]. While the importance of senescent 
fibroblast-derived OPN is underscored by its ability to 
promote preneoplastic cell growth, the regulation of 
OPN in response to senescence is not understood. SASP 
regulators ATM and NF-κB are not required for OPN 
induction in response to senescence [38]. Other SASP 
regulators, such as C/EBPβ, have not been studied in 
conjunction with OPN [27, 29]. Indeed, there are no known 
regulators of OPN in response to senescence. Because of 
senescent-derived OPN’s ability to promote preneoplastic 
cell proliferation, it is important to understand how OPN 
is regulated in this context. Additionally, elucidating the 
regulation of OPN may provide insights into the regulation 
of other SASP factors that are regulated in a similar 
manner.
To identify regulators of OPN, we used an OPN 
promoter reporter to identify a senescence response 
element (SRE) that was required for activation of the OPN 
promoter in response to senescence. Using Transfac® to 
analyze the SRE for transcription factor binding motifs, 
we identified a number of putative regulators of OPN in 
senescence, including C/EBPβ and c-Myb. C/EBPβ is a 
transcription factor with important roles in senescence 
induction and is known to regulate IL-6, IL-8, and other 
SASP factors in response to senescence as well as in 
other contexts [39–41]. Likewise, it has been shown to 
regulate OPN in a lung cancer cell line [42]. c-Myb is a 
proto-oncogene important for hematopoietic development 
[43]. Additionally, c-Myb is a known regulator of OPN 
in hepatocellular carcinoma and melanoma models 
[32, 44]. While Myb family member b-Myb regulates 
proliferation and represses senescence, the Myb family 
transcription factors have distinct roles, and c-Myb has 
not been studied in mammalian cell senescence [45–48]. 
Interestingly, c-Myb and C/EBPβ can collaborate to 
activate transcription of a number of genes, including 
mim-1 and ChAT [49–51]. Therefore, we hypothesized 
that c-Myb and C/EBPβ regulate OPN and other SASP 
factors.
RESULTS
The OPN promoter contains a senescence 
response element
Given the pro-tumorigenic nature of OPN and 
its unique regulation among studied SASP factors, we 
sought to determine the mechanism of OPN regulation 
during senescence. To do so, we used promoter reporter 
constructs composed of regions of the OPN promoter 
driving transcription of luciferase to identify sequences in 
the OPN promoter required for transcriptional activation 
during senescence [52]. To carry out these analyses, BJ 
fibroblasts were transfected with the reporter constructs 
and induced to senesce by treatment with bleomycin 
for 24 hours. Four days after the start of bleomycin 
treatment, when cells displayed a senescent phenotype 
as demonstrated by a flattened morphology and staining 
positive for senescence-associated β-galactosidase (SA-
βgal; Figure 1a), we assessed luciferase activity. We used 
regions of the OPN promoter spanning from the +86 
nucleotide to the upstream site indicated (Figure 1b). 
While the +86 to -135 nucleotide region of the promoter 
had only ~two-fold increase in luciferase activity in 
bleomycin treated cells relative to non-senescent cells, 
the region spanning from +86 to -190 nucleotides had 
4.9-fold increased expression in senescent compared to 
non-senescent fibroblasts. The increased induction of 
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expression observed in response to senescence when the 
-135 to -190 nucleotide region was present suggested that 
this region, which we termed the senescence response 
element (OPN-SRE), contains important senescence-
associated transcription factor binding motifs (Figure 1c).
Transfac® analysis of the OPN-SRE promoter 
region revealed numerous putative binding sites for a 
variety of transcription factors, including HNF1, ZBTB16, 
HMGA1, SOX, FOXH1, C/EBPβ, and c-Myb. Preliminary 
data using shRNA to deplete cells of these transcription 
factors suggested that many were not required for OPN 
induction in response to senescence (data not shown). 
Therefore, we focused on the transcription factors C/EBPβ 
and c-Myb. C/EBPβ regulates the induction of numerous 
SASP factors including IL-6 and IL-8 in response to 
oncogene induced senescence [40]. In contrast, while 
c-Myb transcriptionally activates OPN in several 
epithelial cell models [32, 44], its roles in fibroblasts and 
in senescence are poorly studied. However, c-Myb and 
C/EBPβ can interact and have been shown to co-activate 
transcription of several genes in other settings [53–55]. 
Given these data, we examined C/EBPβ and c-Myb as 
possible regulators of OPN in response to senescence.
C/EBPβ is required for robust OPN expression in 
response to senescence
C/EBPβ regulates the induction of several SASP 
factors including IL-6 and IL-8 in response to oncogene 
induced senescence [40, 56] and has been implicated in 
control of OPN expression in other systems [42, 57, 58]. 
To test whether C/EBPβ was required for the induction of 
OPN in response to senescence, we depleted BJ fibroblasts 
of C/EBPβ using two independent shRNAs (Figure 2a). 
Upon the induction of senescence, C/EBPβ-depleted cells 
displayed reduced OPN expression relative to fibroblasts 
expressing a control short hairpin. Indeed, shC/EBPβ cells 
had 42% and 77% reduced OPN induction (shCEBP_1 
and shCEBP_2, respectively) compared to shLUC 
expressing cells (Figure 2b). In agreement with previous 
studies [40], we found that C/EBPβ depletion also 
reduced IL-6 (39% and 78%, shCEBP_1 and shCEBP_2, 
respectively) and IL-8 (78% and 97%, shCEBP_1 
and shCEBP_2, respectively) induction in response to 
senescence. Interestingly, depletion of C/EBPβ did not 
affect senescence induction in our system as measured by 
SA-βgal and cell growth measurement (Figure 2c-2d). 
To confirm C/EBPβ’s role in regulating OPN, we 
inhibited C/EBPβ in BJ fibroblasts by stably expressing a 
dominant negative form of C/EBPβ, LIP. C/EBPβ has three 
isoforms: LAP1, LAP2, and LIP [59]. LAP1 and LAP2 
are transcriptional activators while LIP, which contains the 
DNA binding domain but lacks the transactivation domain, 
is an inhibitory isoform that acts as a dominant negative 
to the activating isoforms. Compared to empty vector 
controls (Vector), OPN induction was reduced by 59% 
and IL-6 induction by 75% in LIP-expressing cells (DN-
CEBP) in response to senescence (Figure  2e). Importantly, 
inhibition of C/EBPβ did not affect senescence induction 
as measured by SA-β-gal (Figure 2f). Thus, C/EBPβ is 
required for OPN, IL-6, and IL-8 induction in response to 
Figure 1: The senescence-responsive region of the OPN promoter contains c-Myb and C/EBPβ binding sites. a. 
Treatment of BJ fibroblasts with bleomycin induces a significant increase in senescence as indicated by increased senescence-associated 
β-galactosidase staining, n=3, *p<0.05. Scale bar=100 μm b. Schematic of expression of luciferase reporter constructs that were driven 
by fragments of the OPN promoter spanning from nucleotide +86 to the indicated number of bases upstream from the transcription start 
site (TSS; top). BJ fibroblasts expressing the indicated promoter reporter constructs were treated with vehicle or bleomycin to induce 
senescence. Relative luciferase activity in senescent relative to non-senescent fibroblasts indicates a senescence-responsive element (SRE) 
between -135 and -190 bases upstream of the TSS (bottom), n=3. c. Schematic of OPN promoter. The SRE includes putative binding sites 
for the transcription factors c-Myb and C/EBPβ.
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Figure 2: C/EBPβ is required for OPN induction in response to senescence. a. C/EBPβ protein was measured in control or 
shCEBP-expressing cells via Western blot. shCEBP_1 had 64% reduced levels of activating C/EBPβ isoforms (LAP1&2) while shCEBP_2 
had 59% reduced activating C/EBPβ isoforms, n=3. b. OPN, IL-6, and IL-8 mRNA expression were decreased in senescent shCEBP_1 
and shCEBP_2 BJs relative to control (shLUC), n=3, *p<0.05. c. Senescence-associated β-galactosidase (SA-βgal) staining was used to 
measure senescence induction in BJ fibroblasts expressing one of two independent shRNAs targeting C/EBPβ (shCEBP_1, shCEBP_2) 
or a control hairpin (shLUC) and treated with bleomycin (Bleo, left). There is no significant difference in percent SA-βgal+ cells among 
any of the hairpins (right), n=3, n.s.=non-significant, *p<0.05. Scale bar=100 μm d. Cell proliferation over four days in non-senescent or 
bleomycin-treated fibroblasts was not affected by depletion of C/EBPβ, n=3, *p<0.05. e. Expression of OPN and IL-6 are significantly 
reduced in senescent cells expressing dominant negative C/EBPβ (DN-CEBP) relative to empty vector control, n=4, *p<0.05 f. SA-βgal 
staining indicates no change in senescence induction following bleomycin treatment in vector compared to DN-CEBP fibroblasts, n=3, 
n.s.=non-significant, *p<0.05, ***p<0.001. Scale bar=100 μm.
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senescence, but depletion or inhibition does not prevent 
the induction of senescence in our system. C/EBPβ, 
therefore, represents a common factor of the previously 
distinct regulatory pathways of OPN and SASP factors 
such as IL-6 and IL-8.
C/EBPβ binds to the OPN promoter
The promoters of OPN, IL-6 and IL-8 all contain 
C/EBPβ binding sites. To test whether C/EBPβ 
directly binds the OPN promoter, we used chromatin 
immunoprecipitation (ChIP) in non-senescent and 
bleomycin-treated 293T cells. In response to bleomycin, 
there was robust induction of senescence as measured by 
SA-βgal staining (Figure 3a). Because the upregulation 
of many SASP factors is transcription-dependent early 
after a senescence-inducing treatment but less dependent 
on transcription once senescence is fully established, we 
collected cells 48 h after the start of bleomycin treatment 
when transcription was robust [6]. Immunoprecipitation 
with an anti-C/EBPβ antibody that recognizes all three C/
Figure 3: C/EBPβ isoform binds SASP promoters in senescent cells. a. Treatment of 293T HEK cells with bleomycin induces 
a significant increase in senescence as indicated by increased senescence-associated β-galactosidase staining, n=3, *p<0.05. Scale bar=100 
μm. b. Chromatin immunoprecipitation (ChIP) using a C/EBPβ antibody which recognizes all three C/EBPβ isoforms or a non-specific 
control (IgG) indicates that C/EBPβ significantly binds to the OPN and IL-6 promoters in both vehicle and bleomycin-treated 293Ts, and 
to the IL-8 promoter in vehicle treated cells, representative experiment, n=3, *p<0.05. “nspc.” indicates pulldown with C/EBPβ antibody 
at a distal site. c. Western blot using an anti-CEBPβ antibody indicating similar C/EBPβ expression in non-senescent and senescent ChIP 
treatments, n=1. d. ChIP in 293Ts transfected with a Flag-tagged activating C/EBPβ isoform (Flag-LAP2). An antibody recognizing all 
three C/EBPβ isoforms (CEBP) or an anti-Flag antibody was used to detect binding of the total C/EBPβ relative to exogenous Flag-LAP2 
to the OPN, IL-6 and IL-8 promoters in vehicle (Non-Sen) and bleomycin-treated (Sen) 293Ts. While there was little change in total C/
EBPβ bound to the OPN, IL-6, or IL-8 promoters, Flag-LAP2 binding to all three promoters was significantly increased in senescent 
cells, representative experiment, n=3, *p<0.05. e. Western blotting using an anti-Flag antibody indicated that Flag-LAP2 expression is 
significantly higher in non-senescent 293Ts than senescent 293Ts, n=3.
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EBPβ isoforms revealed binding of C/EBPβ to the IL-6 
and IL-8 promoters as has been previously shown (Figure 
3b; [40]). In addition, there was significant binding to the 
OPN promoter in both non-senescent (0.05% input) and 
senescent (0.07% input) cells. Surprisingly, there was no 
significant difference in C/EBPβ binding relative to IgG 
in non-senescent compared to senescent cells. Likewise, 
there was little difference in C/EBPβ expression between 
the two conditions (Figure 3c). Interestingly, binding of 
exogenous Flag-tagged LAP2, an activating isoform of C/
EBPβ, to the OPN, IL-6, and IL-8 promoters increased 
in response to senescence (Figure 3d). We observed this 
effect despite measuring greater Flag-LAP2 expression in 
non-senescent cells than in senescent cells (Figure  3e). 
c-Myb is required for robust OPN expression in 
senescent cells
Having established C/EBPβ as a regulator of 
OPN, we asked whether there were additional regulators 
in response to senescence. Thus, we returned to our 
promoter analysis to identify additional regulators of 
OPN. In addition to the C/EBPβ binding site, the SRE 
of the OPN promoter contains a putative c-Myb binding 
sequence. C-Myb is a proto-oncogene transcription 
factor but has never been implicated in mammalian 
senescence. Furthermore, while c-Myb is not well studied 
in fibroblasts, it has been shown to regulate fibrosis and 
Figure 4: c-Myb regulates OPN, IL-6, and IL-8 in response to senescence. a. Senescence-associated β-galactosidase (SA-
βgal) staining was used to measure senescence induction in bleomycin-treated BJ fibroblasts expressing one of two independent shRNAs 
targeting c-Myb (shMYB_1, shMYB_2) or a control hairpin (shLUC; left). There is no significant difference in percent SA-βgal+ cells 
among any of the hairpins (right), n=3, n.s.=non-significant, *p<0.05. Scale bar=100 μm b. c-Myb, C/EBPβ and p65 protein levels were 
measured in control or shMYB-expressing cells via Western blot. shMYB_1 had 63% c-MYB while shMYB_2 had 55% c-Myb relative 
to control, n=3. c. OPN, IL-6, and IL-8 mRNA expression were decreased in senescent shMYB_1 and shMYB_2 BJs relative to control 
(shLUC), n=3, *p<0.05. d. Cell proliferation over four days in non-senescent or bleomycin-treated fibroblasts was not affected by depletion 
of c-Myb, n=3 *p<0.05, ***p<0.001.
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many factors upregulated in fibrosis are also upregulated 
in senescence [60, 61], raising the possibility that it 
may play a role in regulating SASP factor expression. 
Importantly, c-Myb and C/EBPβ can interact and co-
activate transcription in other contexts, suggesting they 
may act in a similar manner in response to senescence 
[53–55]. Interestingly, we also did not detect any change in 
c-Myb protein levels in response to senescence induction 
(data not shown).
To establish a role for c-Myb in the regulation of 
OPN during senescence, human fibroblasts were depleted 
of c-Myb using two independent short hairpins. Using 
bleomycin to induce senescence (Figure 4a), we measured 
OPN mRNA expression by qRT-PCR. Using two hairpins 
to deplete c-Myb, we observed a 37% and 45% (shMYB_1 
and shMYB_2, respectively) reduction in c-Myb protein 
levels relative to γ-actin (Figure 4b), which resulted in a 
64% and 77% decrease in OPN mRNA induction relative 
to shLUC control (Figure 4c). Importantly, depletion of 
c-Myb did not inhibit senescence-induction, as measured 
by SA-βgal and cell growth assays, indicating that c-Myb 
is necessary for OPN induction but not senescence 
induction (Figure 4a, 4d). In addition, depletion of c-Myb 
had little or no effect on C/EBPβ or NF-κB (p65) protein 
levels (Figure 4b), further indicating that c-Myb acts 
to transcriptionally regulate the SASP, not via indirect 
regulation of these transcription factors. 
C-Myb has not previously been reported to regulate 
the SASP. Therefore, we asked whether c-Myb regulates 
other SASP factors in addition to OPN. Knockdown of 
c-Myb resulted in significantly reduced IL-6 (90% and 
78%, shMYB_1 and shMYB_2, respectively) and IL-8 
(89% and 84%, shMYB_1 and shMYB_2, respectively) 
mRNA expression in response to senescence (Figure 4c), 
indicating that c-Myb regulates multiple SASP factors and 
suggesting that it may broadly regulate C/EBPβ-dependent 
SASP factors.
c-Myb regulates OPN via direct binding and 
activation of the OPN promoter
To test whether c-Myb directly regulates OPN 
transcription, we used chromatin immunoprecipitation 
(ChIP) in 293T cells ectopically expressing c-Myb (Figure 
5a). Ectopic c-Myb was used because we were unable to 
consistently detect binding of endogenous c-Myb. ChIP 
analysis of c-Myb revealed that it is significantly bound 
to the endogenous OPN promoter relative to IgG control 
in both non-senescent (0.007 percent input Myb relative 
to 0.003 IgG) and senescent (0.014 percent input relative 
to 0.002 IgG; Figure 5b) cells. Additionally, c-Myb also 
bound the endogenous IL-6 and IL-8 promoters at similar 
levels, indicating that c-Myb directly regulates SASP 
factors other than a OPN. Further, in senescent cells 
c-Myb significantly bound transiently transfected WT 
OPN190-luciferase promoter reporter construct compared 
to IgG controls (0.34 c-Myb percent input relative to 
0.18 IgG; Figure 5c). However, mutation of the putative 
c-Myb binding site on the OPN190 reporter (OPN190-
MUT MBS) eliminated c-Myb binding (0.10 Myb percent 
input relative to 0.08 IgG), indicating that c-Myb binds 
specifically to this site. While WT OPN190 promoter 
activity is activated 4.3-fold following bleomycin 
treatment, OPN190-MUT MBS is not activated (1.3-fold; 
Figure 5d), indicating that c-Myb binding to the OPN 
promoter is required for the transcriptional induction of 
OPN following senescence induction. While this work 
was done with ectopic c-Myb, the ability to eliminate both 
c-Myb binding to the OPN promoter reporter construct and 
activation of the construct by mutating the c-Myb binding 
site suggests that endogenous c-Myb’s regulation of 
OPN may depend upon its ability to bind the endogenous 
promoter and that our inability to detect its presence on the 
promoter is due insufficient sensitivity in our assay.
c-Myb and C/EBPβ regulate overlapping subsets 
of the SASP
While it has been shown that C/EBPβ regulates 
the SASP, c-Myb has not previously been implicated as 
a SASP regulator. To determine whether c-Myb regulates 
additional SASP factors beyond OPN, IL-6, and IL-8, we 
performed a microarray comparing transcript levels in non-
senescent and senescent BJ fibroblasts expressing either a 
control short hairpin (shLUC) or a hairpin targeting either 
c-Myb or C/EBPβ (shMyb_1 or shCEBP_2, respectively). 
We restricted our analysis to 834 SASP genes, those which 
were significantly upregulated both by bleomycin-induced 
senescence and Ras-induced senescence (Supplementary 
Table 1). We compared the gene fold-upregulation in 
bleomycin-treated cells relative to untreated cells in the 
shLUC, shMYB_1, and shCEBP_2 groups. Comparing the 
fold-upregulation between groups, we found that 127/834 
genes were C/EBPβ-dependent (Figure 6a, Supplementary 
Table 2). Importantly, 59/834 genes were c-Myb-
dependent (Supplementary Table 3). Interestingly, 47/59 
c-Myb-dependent genes were also C/EBPβ-dependent, 
suggesting c-Myb largely regulates C/EBPβ-dependent 
genes. We performed GO Term enrichment analysis on 
the SASP, C/EBPβ-dependent, and c-Myb-dependent gene 
sets. There were no significant enrichments among these 
gene sets relative to each other. However, the SASP was 
enriched for expected terms such as chemokine, cytokine, 
and extracellular matrix glycoprotein relative to the 
genome. Further, both C/EBPβ and c-Myb were similarly 
enriched for the terms chemokine, cytokine, and serine 
protease inhibitor. 
In accordance with our qPCR findings, IL-6 and 
IL-8 are among the C/EBPβ- and c-Myb-dependent genes 
(Figure 6b). However, while OPN induction was reduced 
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in shC/EBPβ and shMyb cells, this reduction was not 
significant. This difference was significant when measured 
by qPCR (Figure 4c), suggesting that the microarray 
data lacks sufficient power to find significance for genes 
with smaller changes. Therefore, our analysis likely 
underestimates the number of genes regulated by both C/
EBPβ and c-Myb.
In addition to the genes we had already studied, we 
used qPCR to validate CXCL5, IL1β, and MMP1, three 
genes which were significantly dependent on both C/
EBPβ and c-Myb in our microarray data. All three genes 
recapitulated the microarray results (Figure 6c). These 
data suggest that c-Myb is an important regulator of many 
C/EBPβ-dependent SASP genes in addition to OPN, IL-6, 
and IL-8.
c-Myb and C/EBPβ knockdown inhibits 
preneoplastic cell growth promotion by senescent 
fibroblasts
Senescent fibroblasts promote the growth of 
neoplastic and preneoplastic epithelial cells in coculture 
and xenograft models via secretion of SASP factors [7, 
Figure 5: OPN induction in senescent cells requires c-Myb binding to the OPN promoter. a. Western blot showing total 
c-Myb expression in the non-senescent and senescent cells used for ChIP. b. Chromatin immunoprecipitation was used to measure c-Myb 
binding to the OPN, IL-6, and IL-8 promoters in 293T cells expressing exogenous c-Myb cDNA. C-Myb significantly binds to all three 
endogenous promoters relative to IgG control, representative experiment, n=3, n.s.=non-significant, *p<0.05. “nspc.” indicates pulldown 
with c-Myb antibody at a distal site. c. c-Myb binds the OPN190 promoter reporter construct relative to IgG control. Mutation of the c-Myb 
binding site (mutations indicated below) eliminates binding to the OPN190 construct, n=3, n.s.=non-significant, *p<0.05. d. Luciferase 
activity is increased in senescent BJ fibroblasts expressing the WT OPN190 construct relative to non-senescent cells, but not in fibroblasts 
expressing the mutant c-Myb binding site OPN190 construct (OPN190MUT MBS), n=4, n.s.=non-significant, *p<0.05. 
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37]. Depletion of OPN in senescent BJ skin fibroblasts 
is sufficient to eliminate the growth promotion that 
senescent BJ fibroblasts provide to HaCAT preneoplastic 
keratinocytes [7]. Because c-Myb and C/EBPβ regulate 
OPN and other SASP factors, we tested whether depletion 
of c-Myb and C/EBPβ would reduce the growth advantage 
provided by senescent cells using this same skin carcinoma 
coculture model.
HaCAT cells stably expressing click beetle red 
luciferase were plated on top of a confluent monolayer of 
1.3x103 non-senescent or senescent fibroblasts in serum-
free media and allowed to grow for six days (Figure 
7a). Recapitulating previous work, senescent fibroblasts 
dramatically increased HaCAT cell growth as measured 
by live cell imaging [7, 37]. However, this growth was 
significantly lower for HaCAT cells cocultured with 
either shC/EBPβ or shMyb expressing fibroblasts (Figure 
7b), indicating the importance of C/EBPβ and c-Myb in 
regulating the SASP and its downstream pro-tumorigenic 
effects.
DISCUSSION
The SASP plays important roles in wound healing 
and pathology, including the promotion of tumor 
development. Thus, understanding the complex regulation 
of the SASP will provide opportunities for therapeutic 
intervention. Many regulators of the SASP have been 
identified. However, it is clear that not all SASP factors 
are regulated by the same pathways. The SASP factor 
OPN is a potent pro-tumorigenic factor and is involved 
in numerous other physiological and pathological 
pathways such as bone turnover and the development of 
kidney stones [31, 62]. Previous work by our laboratory 
found that OPN is not dependent on the canonical SASP 
regulators ATM and NF-κB [38], illustrating that SASP 
factors are not subject to a single regulatory program.
We have identified C/EBPβ and c-Myb as critical 
Figure 6: c-Myb and C/EBPβ regulate a subset of the SASP. a. A microarray was performed to compare gene expression and 
induction in response to senescence among control, shCEBP_2 and shMYB_1 expressing fibroblasts. 834 genes were identified as SASP 
factors. Of these, 127 were solely C/EBPβ dependent, 12 were solely c-Myb dependent, and 47 were dependent on both transcription 
factors. Genes were considered dependent if their induction in response to senescence was significantly reduced in the experimental hairpin 
condition relative to control, p<0.05. b. The log2 fold change in induction (bleomycin over non-senescent) of shLUC relative to shCEBP_2 
or shMYB_1 is plotted relative to the negative log10 of the p-value. Genes with significantly higher (bright colors, right) or lower (pale 
colors, left) induction in shLUC relative to shCEBP (circles) or shMYB (open boxes) are indicated. c. The C/EBPβ- and c-Myb-dependent 
SASP factors MMP1, CXLC5, and IL1B were validated using qRT-PCR. Depletion of C/EBPβ or c-Myb with two different hairpins each 
significantly reduced induction of these SASP factors.
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regulators of the pro-tumorigenic SASP factor OPN. 
Depletion of C/EBPβ using shRNA and dominant 
negative inhibition significantly decreased OPN induction 
in response to senescence (Figure 2b, 2e). As has been 
previously reported, C/EBPβ is also required for the 
induction of IL-6 and IL-8 [40]. However, in contrast to 
that study which used an oncogene-induced senescence 
model, we did not observe a decrease in senescence 
induction in response to C/EBPβ depletion or inhibition 
(Figure 2a, 2d, 2f). While the cause of this difference is not 
clear, it may be due to differences in cell type, senescence-
induction, or the level of C/EBPβ depletion. Nonetheless, 
the robust senescence induction observed, together with 
our ChIP data (Figure 3b, 3d), indicate that OPN is directly 
regulated by C/EBPβ and is not simply induced indirectly 
by the senescence program.
While C/EBPβ has previously been reported as an 
important SASP regulator, very little has been published 
about the mechanism of C/EBPβ activation of SASP 
genes. We observed that although there is no significant 
change in total C/EBPβ binding to the OPN, IL-6, or 
IL-8 promoters, binding of an exogenously expressed, 
activating form of C/EBPβ, Flag-LAP2, significantly 
increases in response to senescence (Figure 3b, Figure 3d). 
These data suggest that C/EBPβ regulation of SASP factor 
transcription may be more complex than simple binding, 
but require changes in specific isoform binding.
Our data establish that c-Myb is a novel regulator 
of components of the SASP. Depletion of c-Myb using 
shRNA significantly decreased the induction of OPN, 
IL-6, and IL-8 in response to senescence (Figure 4c). 
An additional 57 putative target factors were identified 
via microarray (Figure 6a), and three of these putative 
targets (MMP1, CXCL5, and IL1B) were validated with 
qRT-PCR (Figure 6c). The regulation of at least some of 
these genes may be direct, as exogenous c-Myb binds 
directly to the OPN, IL-6, and IL-8 promoters in both non-
senescent and senescent cells (Figure 5b). Interestingly, 
despite lower ectopic c-Myb expression in senescent cells 
(Figure 5a), there is an increase in promoter occupancy 
in senescent cells relative to non-senescent, which, while 
non-significant, raises the possibility that c-Myb may 
increase binding to the promoters of some SASP factors 
in response to senescence. Using ChIP on exogenously 
transduced plasmids we were able to show that mutation of 
the c-Myb binding site on the OPN promoter disrupts this 
binding and abrogates promoter activation in response to 
bleomycin (Figure 5c-5d), suggesting that c-Myb binding 
is required for the activation of the promoter. Together 
these data indicate that c-Myb is critical for the induction 
of not only OPN, but a larger subset of the SASP. Although 
c-Myb has not been extensively studied in fibroblasts, one 
of its known roles is regulating fibrosis [60, 61]. Here we 
show that c-Myb regulates SASP factors, including matrix 
Figure 7: Depletion of c-Myb or C/EBPβ inhibits preneoplastic cell growth promotion by senescent fibroblasts. a. 
HaCAT keratinocytes expressing CBR luciferase were cocultured with non-senescent or senescent BJs expressing either a control shRNA 
(shLUC) or shRNAs targeting C/EBPβ (shCEBP_1 and shCEBP_2) or c-Myb (shMYB_1 and shMYB_2). HaCAT proliferation was 
measured using bioluminescent imaging after six days of coculture, shown as fold growth when cocultured with senescent fibroblasts 
relative to non-senescent fibroblasts. b. Depletion of either C/EBPβ or c-Myb in senescent BJ fibroblasts significantly reduces the ability 
to promote HaCAT cell growth, n=3, *p<0.05. c. Schematic showing the proposed model of regulation of OPN and other SASP factors 
by c-Myb and C/EBPβ. In response to senescence, the activating isoform of C/EBPβ, LAP2, increases occupancy on the SASP promoter, 
inducing transcription.
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proteins OPN and MMP1, suggesting that c-Myb plays 
an important role in regulating the extracellular matrix in 
multiple physiological contexts.
C/EBPβ and c-Myb commonly act as co-activators 
of transcription [49–51]. Our data indicate that both 
transcription factors are required for the induction of 
OPN. In addition, via microarray analysis, we identified 
47 additional SASP genes which are dependent on both C/
EBPβ and c-Myb (Figure 6a). Only 12 c-Myb-dependent 
factors were not also C/EBPβ-dependent, indicating that 
c-Myb generally regulates C/EBPβ-dependent factors. We 
hypothesize that C/EBPβ and c-Myb interact to activate 
a cohort of SASP factors, but more work is needed to 
investigate whether these mechanisms studied in other 
contexts are also at play in senescent cells.
C/EBPβ and c-Myb are functionally important 
for the ability of senescent cells to promote the growth 
of pre-neoplastic HaCAT keratinocytes in a cocultures 
setting (Figure 7b). Depletion of either C/EBPβ or c-Myb 
significantly reduced the ability of senescent cells to 
promote HaCAT cell growth. Interestingly, depletion of C/
EBPβ in non-senescent cells actually increased the growth 
promotion, but the mechanism of this increased growth is 
not known.
While OPN upregulation in senescence is 
independent of ATM and NF-κB, it does require C/
EBPβ and c-Myb for expression. C/EBPβ and c-Myb 
also regulate IL-6, IL-8, and other NF-κB-dependent 
genes, suggesting that there are not simply distinct SASP 
master regulatory pathways, but multiple SASP regulators 
which act together and separately in a complex network 
to regulate the individual factors that are collectively the 
SASP. More work is needed to understand the interplay 
among the various regulatory pathways and which factors 
they regulate.
MATERIALS AND METHODS
Cell lines and treatments
Human foreskin BJ fibroblasts and 293T cells were 
cultured as previously described [7]. HaCAT preneoplastic 
keratinocyte cells stably expressing click beetle red (CBR) 
luciferase (HaCAT-CBR) and HEK 293T cells were grown 
in DMEM containing 10% heat-inactivated FBS and 
1% penicillin/streptomycin (Sigma; [7]). All cells were 
cultured at 37°C in 5% carbon dioxide and 5% oxygen.
Cells were treated with 0.1 U/mL bleomycin 
sulfate (Sigma) for 24 hours. Cell pellets were collected 
96 hours after the start of bleomycin treatment and RNA 
was isolated using TRI Reagent (Life Technologies) and 
Ambion RNA Isolation kit (ThermoFisher).
Plasmids
OPN promoter luciferase constructs consisted of 
a fragment of the OPN promoter driving expression of 
luciferase in the pGL3 vector [52]. Fragments used were 
OPN80 (nucleotide [nt] -80 to nt +86), OPN108 (nt -108 
to nt +86), OPN135 (nt -135 to nt +86), OPN190 (nt 
-190 to nt +86), and OPN400 (nt -400 to nt +86). The nt 
reported correspond to those upstream (-) or downstream 
(+) of the transcriptional start site. The OPN-LUC 
promoter constructs were a gift from the Paul C. Kuo 
Lab [52]. OPN190-LUC mutant c-Myb binding site was 
created using QuikChange II Site-Directed Mutagenesis 
(Agilent) and by following manufacturer’s protocol. The 
c-Myb binding site was changed from 5’-ttaactgtagatt-3’ 
to 5’-ttgctagtagact-3’. pCMV-FLAG-LAP2 (Addgene 
plasmid #15738) and pBabe-puro LIP (Addgene 
plasmid #15713) were gifts from Joan Massague [63]. 
pCDNA3.1-Myb was a gift of Dr. Robert Rosenberg. 
pWZL hygro H-Ras V12 was a gift from Scott Lowe 
(Addgene plasmid # 18749, [10]). shMyb_2 (pSIREN-
RetroQ-MYB-shRNA) was a gift from Judy Lieberman 
(Addgene plasmid # 25790; [64]). All other shRNA 
constructs were obtained from the Children’s Discovery 
Institute’s viral vector-based RNAi core at Washington 
University in St. Louis and were supplied in the pLKO.1-
puro backbone. The sequences are as follows: shLUC 
(5’-TCACAGAATCGTCGTATGCAG-3’), shCEBP_1 
(5’-CGACTTCCTCTCCGACCTCTT-3’), shCEBP_2 
(5’-GCACAGCGACGAGTACAAGAT-3’), shMYB_2 
(5’-CCAGATTGTAAATGCTCATTT-3’).
SA-βgal
Senescence-associated-β-galactosidase staining was 
carried out as previously described [7].
Growth assay
50,000 untreated or bleomycin-treated BJ fibroblasts 
expressing the indicated short hairpins were plated 96 
hours after the start of treatment as previously described. 
Cell number was counted daily for four days using a 
hemocytometer. Significance was determined using a 
2-way ANOVA with Bonferroni post-test.
Western blot
Cell pellets were lysed in buffer containing 50 
mM Tris pH 8.0, 5 mM EDTA, 0.5% NP-40, and 100 
mM sodium chloride for 20 minutes at 4°C. Protein 
concentration was quantified using the Bradford Protein 
Assay (Bio-Rad). Membranes were blocked for one 
hour in 5% milk in TBS-T. The primary antibodies 
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used were mouse monoclonal anti-FLAG M2 (Sigma; 
catalog number F1804) diluted 1:1000; rabbit polyclonal 
anti-C/EBPβ (Santa Cruz sc-150) diluted 1:2500; rabbit 
polyclonal anti-c-Myb rabbit polyclonal (Santa Cruz 
sc-517) diluted 1:250; and anti-γ-actin (Novus; catalog 
number NB600-533) diluted 1:5000. All secondary 
antibodies from the appropriate species were horseradish 
peroxidase–conjugated (The Jackson Laboratory) and 
diluted at 1:10,000. All antibodies were diluted in 2% BSA 
(Sigma-Aldrich) in TBS-T or 1% milk in TBS-T.
Viral transduction
Viral transduction was performed as previously 
described [7]. All constructs were stably expressed using 
viral transduction unless otherwise noted.
Luciferase reporter assay
BJ fibroblasts were transiently co-transfected 
with pGL3-Renilla and pGL3-OPN constructs using 
Lipofectamine 2000 (Thermo Fisher Scientific) and 
promoter activity was determined 48 hours later using 
Promega Dual Luciferase Reporter Assay (Promega) by 
following manufacturer’s protocol.
Chromatin immunoprecipitation
Cells were transiently transfected with pcDNA-
c-Myb WT (Myb), pGL3-OPN190 (OPN190), pGL3-
OPN190 mutant c-Myb binding site (OPN190 Mut), or 
pCMV-Flag-LAP2 in 15 cm plates using 7 µg DNA and 
the TransIT® LT1 Reagent transfection system (Mirus). 
Cells were fixed 48 hours later using 1% formaldehyde 
in PBS for 20 minutes. Fixation was quenched with 125 
mM glycine for 5 minutes with gentle rotation, cells 
were washed with PBS and collected by scraping and 
centrifugation at 200xg for 5 minutes at 4°C. Cells were 
lysed in 2 mL lysis buffer (1% SDS, 10 mM EDTA, 
50 mM Tris pH 8.1) containing protease inhibitors 
(pepstatin, 1 μg/mL; aprotinin, 1 μg/mL; leupeptin, 1 
μg/mL; PMSF, 100 μM) for 15 minutes. The lysate was 
sonicated at 50 Amps with 30 s on, 30 s off for 6 rounds 
to achieve DNA fragments approximately 200-500 bp in 
length as measured by electrophoresis. One mg protein 
was used for each immunoprecipitation. Lysate was 
diluted fivefold into ChIP dilution buffer (0.01% SDS, 
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl 
pH 8.1, 167 mM NaCl) and incubated at 4°C overnight 
with 5 μg appropriate antibody with vertical rotation. 
Antibodies used: anti-Myb (Santa Cruz sc-517); anti-C/
EBPβ (Santa Cruz sc-150); Rabbit IgG (Cell Signaling 
2729); anti-Flag M2 (Sigma F1804); mouse IgG1 (for 
Flag ChIPs, Cell Signaling 5415). Primers used: OPN 
TSS (Taqman assay # AJRR84Z), OPN190 (binds to the 
plasmid only; F:CTTTATGTTTTTGGCGTCTTCCA, 
R: CTAGCAAAATAGGCTGTCCC), IL-6 promoter 
(F: 5’-GCCATGCTAAAGGACGTCACA-3’, R: 
5’-GGGCTGATTGGAAACCTTATTAAGA-3’), IL-8 
promoter (F: 5’-AAGTGTGATGACTCAGGTTTGC-3’, 
R: 5’-GCACCCTCATCTTTTCATTATG- 3’), OPN 
distal (F: 5’-GTGGCTTCATGGAAACTCCCT-3’, 
R; 5’-GGACAACCGTGGGAAAACAA), IL-6 
distal (F: 5’-CCATCCTGAGGGAAGAGGG-3’, R: 
5’-CGTCGGCACCCAAGAATTT- 3’), IL-8 distal 
(F: 5’-TTTGGAGAGCACATAAAAACATC-3’, R: 
5’-CAGCCAAAACTCCACAGTCA-3’).
Quantitative PCR
cDNA synthesis and quantitative PCR was performed 
using manufacturer’s instructions (SYBR Green, Life 
Technologies and Taqman, Applied Biosystems). Primers 
used: GAPDH (F: GCATGGCCTTCGGTGTCC, 
R: AATGCCAGCCCCAGCGTCAAA), 
IL-6 (F: ACATCCTCGACGGCATCTCA, 
R: TCACCAGGCAAGTCTCCTCA), IL-8 
(F: GCTCTGTGTGAAGGTGCAGT, R: 
TGCACCCAGTTTTCCTTGGG), OPN 
(F: TTGCAGCCTTCTCAGCCAA, R: 
AAGCAAATCACTGCAATTCTC), c-Myb 
(IDT PrimeTime® Std qPCR assay #Hs.
PT.58.264008, Probe: 5’-56-FAM/CCTTCCGAC/
ZEN/GCATTGTAGAATTCCAGT/3IABkFQ/-3’, 
F: 5’-CTCCTGCAGATAACCTTCCTG-3’, R: 
5’-GCAGAAATCGCAAAGCTACTG-3’), C/
EBPβ (Taqman assay # Hs00270923_s1), 
MMP1 (IDT PrimeTime® Std qPCR assay #Hs.
PT.58.38692586, Probe: 5’-56-FAM/TCCGTGTAG/
ZEN/CACATTCTGTCCCTG/3IABkFQ/-3’, 
F: 5’-GCCAAAGGAGCTGTAGATGTC -3’, 
R: 5’-GACAGAGATGAAGTCCGGTTT -3’), 
CXCL5 (IDT PrimeTime® std qPCR assay #Hs.
PT.58.41058007.g, Probe: 5’-/56/FAM/CGGGGAGGG/
ZEN/CAGGGAAGATG/3IABkFQ/-3’, F: 
5’-GAACAGGCTTTACATTCAGACAG-3’, 
R: 5’-GGGTTAGAGGATTGCAGAAGA-3’), 
IL1β (IDT PrimeTime® std qPCR assay #Hs.
PT.58.1518186, Probe: 5’-/56-FAM/AGAAGTACC/
ZEN/TGAGCTCGCCAGTGA/3IABkFQ/-3’, 
F: 5’-GAACAAGTCATCCTCATTGCC-3’, R: 
5’-CAGCCAATCTTCATTGCTCAAG-3’).
Microarray
Microarray analysis was performed by the Genome 
Technology Access Center at Washington University. Cells 
expressing shLUC were senesced using bleomycin or Ras 
expression. Further analysis was restricted to genes that 
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were either significantly up- or down-regulated in both 
bleomycin and Ras groups. Fold changes in bleomycin 
relative to untreated groups were then compared between 
the shLUC, shCEBP_2, and shMYB_1 groups. Two 
biological replicates for each group were analyzed. 
Statistical analysis was done using linear model fitting and 
the R package limma using an adjusted p-value<0.05 as 
the cutoff for significance [65,66]. GO Term Enrichment 
Analysis was performed using the Gene Ontology 
Consortium PANTHER software version 11.1 (released 
2016-10-24) and the PANTHER Overrepresentation Test 
(released 2016-07-15). The PANTHER protein class 
annotation was used and our datasets were compared to the 
Homo Sapiens reference list with Bonferroni correction 
for multiple comparisons [67].
Coculture
Coculture experiments were performed as 
previously described with the following modifications [7]. 
A total of 1.3 × 104 fibroblasts were plated in black-walled 
96-well plates (Fisher Scientific). Cells were incubated in 
starve medium (DMEM + 1% penicillin/streptomycin) for 
3 days before the addition of HaCAT-CBR cells. HaCAT-
CBR cells were cultured in starve medium for 24 hours 
before plating on fibroblasts. A total of 1.0 × 103 HaCAT-
CBR cells were plated on fibroblasts and incubated for 
six days.   On day six, live-cell bioluminescence imaging 
was performed on an IVIS 50 (PerkinElmer; Living Image 
4.3, 1 min exposure, bin8, FOV12cm, f/stop1, open filter). 
D-luciferin (150mg/ml; Gold Biotechnology, St. Louis, 
MO) was added to black-walled plates 10 min prior to 
imaging.
Statistical analysis
Data is presented as the mean ± SEM. Student’s 
t-test was used to determine significance when comparing 
two groups. When comparing three or more groups, one-
way ANOVA with Dunnett’s post-test was used, except 
where noted. In all cases, a p-value less than 0.05 was 
considered significant. 
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